Trial Number
681-26
Condition
Lung Cancer
Participant Age Range
18 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer”
Researchers are studying an investigational medication called pumitamig, given with chemotherapy before surgery, for adults with newly diagnosed, early-stage non-small cell lung cancer (NSCLC) that can be surgically removed. Participants will receive one of two doses of pumitamig with platinum-based chemotherapy for up to four treatment cycles, followed by surgery. Researchers will evaluate how well the treatment eliminates cancer cells from the tumor and lymph nodes, as well as its safety, effects on surgery, and whether the cancer returns. Participants may be followed for up to approximately five years.